Cara Therapeutics Inc (CARA)

8.58
0.04 0.46
NASDAQ : Health Care
Prev Close 8.62
Open 8.83
Day Low/High 8.08 / 8.90
52 Wk Low/High 4.26 / 23.61
Volume 1.92M
Avg Volume 821.60K
Exchange NASDAQ
Shares Outstanding 27.28M
Market Cap 211.44M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

This Is Just Routine Churning

This Is Just Routine Churning

We are still a bit extended and it isn't surprising to see a pause.

Trade-Ideas: Cara Therapeutics (CARA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Cara Therapeutics (CARA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Cara Therapeutics (CARA) as a strong on high relative volume candidate

Minor Weakness Doesn't Deter Buyers

Market's junk stocks attract traders.

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.

Cara Therapeutics Initiates Adaptive Phase 2/3 Trial Of I.V. CR845 For Treatment Of Chronic Kidney Disease-Associated Pruritus

Cara Therapeutics Initiates Adaptive Phase 2/3 Trial Of I.V. CR845 For Treatment Of Chronic Kidney Disease-Associated Pruritus

Trial to evaluate multiple doses of I.V. CR845 versus placebo in up to 400 dialysis patients

First Week of February 2017 Options Trading For Cara Therapeutics (CARA)

First Week of February 2017 Options Trading For Cara Therapeutics (CARA)

Investors in Cara Therapeutics Inc saw new options become available this week, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Cara Therapeutics Resumes Patient Recruitment For Adaptive Phase 3 Trial Of I.V. CR845 In Postoperative Pain

Cara Therapeutics Resumes Patient Recruitment For Adaptive Phase 3 Trial Of I.V. CR845 In Postoperative Pain

Trial to evaluate two doses of I.V. CR845 versus placebo following various types of abdominal surgery

These 7 Stocks Under $10 Are About to Break Out

These 7 Stocks Under $10 Are About to Break Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

6 Breakout Stocks Under $10 Set to Soar

6 Breakout Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

4 Top Stocks in the Growing Medical Marijuana Industry

4 Top Stocks in the Growing Medical Marijuana Industry

Weed has gone from a taboo substance to a multi-billion-dollar bonanza. The growth of the marijuana sector has created opportunities for investors. Here are four to watch.

Marijuana Companies Evolving and Scaling to List on Nasdaq, Attract Investors

Marijuana Companies Evolving and Scaling to List on Nasdaq, Attract Investors

The burgeoning marijuana industry is ramping up its efforts to attract both institutional and typical investors by attempting to list on the Nasdaq and through crowdsourcing.

Cara's Recent Dip Is an Entry Chance

This stock is undervalued and has good products in the pipeline.

Today's Weak On High Volume Stock: Cara Therapeutics (CARA)

Today's Weak On High Volume Stock: Cara Therapeutics (CARA)

Trade-Ideas LLC identified Cara Therapeutics (CARA) as a weak on high relative volume candidate